Animals continue to be used in cancer research as *in vivo* studies to help elucidate mechanisms involved in the development/pathology of cancers and are used to improve diagnostic methods and treatment. A recent working party report concluded that studies involving animals remain essential in cancer research but that it is necessary to integrate the 3Rs (Replacement, Reduction and Refinement) into this work as the appropriate use of animals is a prerequisite to good science ([@bib29]). The 3Rs proposed by William Russell and Rex Burch in 1959 refer to the *replacement* of animals used in research with non-sentient alternatives, the *reduction* of the number of animals used in research and the *refinemen*t of experimental and husbandry procedures to minimise pain and distress ([@bib23]).

The application of appropriate and objective humane end points is essential when refining *in vivo* cancer research to minimise pain and/or distress. Humane end points refer to 'criteria that allow early termination of experiments before animals experience significant harm while still meeting the experimental objectives\' ([@bib19]). One of the main obstacles to implementing humane end points is a general lack of biomarkers that can be used as specific indicators of disease progression ([@bib5]), and this has been identified as a particular concern in *in vivo* cancer research ([@bib29]). Although sometimes tumour burden and disease progression can be directly measured using callipers (e.g., subcutaneous tumours) in many other cancer studies (e.g., thoracic, peritoneal and lymphoreticular tumours), it cannot.

Imaging is frequently advocated as a method of tracking disease progression in animals with cancer but repeated anaesthesia is typically required, which may affect experimental outcomes and have a welfare cost ([@bib29]; [@bib28]). Furthermore, imaging is financially costly, requires specialist skills and equipment, and may not be carried out at a sufficient frequency to detect critical points in disease progression. The use of specific clinical signs as biomarkers has the advantage that they can be obtained quickly and non-invasively. Weight loss is the most frequently used clinical biomarker in disease studies, but reliance on changes in body weight as a single indicator of disease progression is problematic ([@bib5]) particularly in cancer research due to the weight of the tumours.

The aim of this study was therefore to identify biomarkers of disease progression in mice with lymphoma. Rather than use animals specifically for this study, enhanced monitoring of wild-type mice implanted with E*μ*-*myc* tumours that were involved in an ongoing programme of work was carried out. Transgenic E*μ*-*myc* mice are widely used to study haematological malignancies and are known to develop aggressive lymphoma ([@bib10]). This strain is frequently crossed with other genetically altered mice (e.g. with altered anti-apoptotic factors, Bcl-xl, Mcl-1) to investigate the effects of different genes *in vivo* ([@bib2]; [@bib14]) and to test the efficacy of novel therapeutic agents ([@bib4]; [@bib26]). In order to minimise the heterogeneity and spontaneity of the tumours, primary tumour cells are frequently obtained from the lymphoid organs of E*μ*-*myc* animals, grown *ex vivo* and implanted into multiple syngeneic recipients. Mice implanted with E*μ*-*myc* tumours typically develop enlarged lymph nodes, spleens and thymus by 2--4 weeks post implantation. However, there is often considerable variation in disease progression depending on the primary tumour implanted making it challenging to apply appropriate humane end points.

We hypothesised that body temperature might predict tumour burden in mice implanted with E*μ*-*myc* tumours. Temperature has been used as a surrogate marker of imminent death in many fields of *in vivo* research ([@bib21]), and in cancer studies persistent hypothermia has been identified as a severe clinical sign necessitating immediate intervention ([@bib29]). Thermoregulation in mice is known to be energetically expensive ([@bib7]), but there is a lack of detailed information on how body temperature changes in mice developing cancer. A secondary hypothesis was that directly measuring food and water would provide an earlier predictor of disease onset at the cage level compared with mean body weight.

Materials and Methods
=====================

All procedures were carried out under project and personal licences approved by the Secretary of State for the Home Office, under the United Kingdom\'s 1986 Animal (Scientific Procedures) Act and approved by Newcastle University\'s Animal Welfare and Ethical Review Body. Thirty-six wild-type male C57BL/6 mice obtained from Charles River Laboratories (Ramsgate, Kent, UK) were studied. Animals were free from all major pathogens and drug and test naive. Mice were housed in groups of 6 per cage in individually ventilated cages (IVCs) (580 cm^3^, Maxiseal 580, Arrowmight, Hereford, UK) with 20 air changes per hour. Aspen woodchips (Tapvei, Datesand, Manchester, UK) and nesting material (1 nestlet/3 mice (FDA Nestlets, Datesand, Manchester, UK)) were used as bedding. Tap water and commercial pelleted diet (R&M no.3, SDS limited, Whitham, UK) were available *ad libitum*. The room was maintained at 23 °C±1 °C on a light cycle (12 h/12 h, lights on at 0700 hours).

Transponder implantation was carried out 3 days before tumour implantation by briefly anaesthetising mice with isoflurane then subcutaneously injecting a transponder (2.2 × 14 mm; 0.12 g; IPTT-300, PLEXX BV, ELST, The Netherlands) into each animal. An automated reader system (Vertical Smart Probe (VSP-7005)/DAS-8001 Data Acquisition System/DAS-7001 wireless interface (PLEXX BV, ELST, The Netherlands)) was used to read temperatures. Temperatures were taken 5--7 days/week between 0800 and 1100 hours by sequentially taking cages off the IVC rack, removing cage lids then placing readers directly adjacent to the cage ([Figure 1](#fig1){ref-type="fig"}) for ∼5 min. Readings were obtained (animal identification/time/temperature) each time a mouse was within reading range (5--8 cm) of the reader. Values greater than 40 °C or less than 33 °C and values that changed more than 3 °C within any 30 s period were considered as outliers and excluded. Daily temperature for each animal was the first valid temperature recorded. The food and water consumption of each cage was also measured daily by weighing the food hopper/water bottle and subtracting the measured weight of food/water from the amount measured the previous day. Mice were weighed following temperature readings.

Mice were randomly allocated to cage and tumour groups. Animals were 8 weeks old with a mean body weight of 22.7 g (s.e.m.=0.25 g) when they were implanted with E*μ*-*myc* tumour cells. Cells had been collected from spontaneous lymphoid tumours of E*μ*-*myc* transgenic animals, frozen and cryogenically stored as previously described ([@bib18]). Tumour cells were then re-implanted into other animals by intravenous injections via the lateral tail vein of 1 × 10^6^ viable cells in a phosphate-buffered saline vehicle. Three primary tumours were used and each was injected into 12 mice (1 primary tumour/2 cages). Clinical signs were recorded daily for each individual mouse, using clinical observation sheets ([@bib11]). Mice were killed at pre-determined experimental end points 2, 3, 4 and 5 weeks post administration (3 mice killed/primary tumour at each experimental end point) unless pre-defined severity limits were approached or met. Mice were killed earlier than their planned experimental end point if 2 experienced researchers (JEH, CAR) considered disease severity to be moderate based on clinical impression or if they exhibited any of the clinical signs listed by [@bib29] as necessitating immediate intervention. Mice were killed by an overdose of isoflurane, and organs were subsequently collected and weighed. As lymphoma causes an enlargement of lymphoid organs, tumour burden was measured as the gross weight of the pooled lymph nodes (cervical, brachial, inguinal and mesenteric), thymus and spleen.

All statistical analyses were conducted using IBM SPSS 19 software (IBM SPSS Inc, Armonk, NY, USA). The experimental unit for all analyses was mouse with the exception of food/water consumption where the cage was the experimental unit (individual food and water consumption could not be measured in standard individually ventilated cages). Because of the variation in baseline values, changes in parameters over the course of the study were studied (e.g., change from baseline values in body temperature, body weight and food/water consumption). Change in body temperature over the course of the study was calculated for each mouse as the difference between mean temperature over the 3 days before killing and the 3 days following tumour implantation. Proportional weight loss for each individual was calculated as the difference between final and maximum body weight compared with maximum body weight (e.g., a mouse with a peak body weight of 30 g over the course of the study who weighed 28 g at the end point would be considered to have a proportional weight loss of 6.7%). The comparison was made with maximum body weight (rather than baseline body weight) as growing mice were studied.

Simple linear regression was used to test whether clinical signs (e.g., change in body temperature, proportional weight loss) predicted tumour burden/weight in the lymphoid organs (pooled lymph nodes, thymus and spleen) of each mouse. Fisher\'s exact test was used to test for association between clinical parameters (change in temperature and weight loss) and tumour burden/ weight of pooled lymph nodes. Differences in post-mortem organ weight were evaluated using a multivariate general linear model with time point and tumour as between-subject factors and pooled lymph node, thymus and spleen weights as within-subject factors. One sample *t*-tests with a Bonferonni correction were used to test for an overall change in food/water consumption. Simple linear regression was also used to test whether mean decrease in food and water consumption in each cage predicted mean tumour burden/weight of the lymphoid organs of the animals in the cage at 3 weeks. Proportional decrease in food/water consumption was calculated as change in mean consumption from experimental week 3 to 1 compared with mean consumption at experimental week 1 (e.g., a cage of mice that consumed an average of 3 g per day over experimental week 1 and 2 g per day over experimental week 3 would have a decrease in food consumption of 33%.). Significance for all statistical tests was established at *P*\<0.05, data are presented as mean (±s.e.m.).

Results
=======

One mouse implanted with tumour 2 was killed on experimental day 0 following an unsuccessful intravenous injection. Clinical signs observed when humane end points were implemented included ruffled coat, enlarged cervical lymph nodes and dull demeanour ([Figure 1B](#fig1){ref-type="fig"}). With the exception of enlarged lymph nodes, none of the mice exhibited clinical signs listed by [@bib29] as necessitating immediate intervention. On the basis of clinical impression, primary tumour 1 was the least aggressive; none of the mice implanted with tumour 1 were killed earlier than pre-determined experimental end points. Six mice from each of experimental groups implanted with primary tumours 2 and 3 were killed earlier than pre-determined experimental end points of 4 and 5 weeks (mice killed days 21--23 and classified as being killed at the 3 week time point).

Six of the RFID transponders failed over the first 7 experimental days (three from tumour group 1, two from tumour group 2, one from tumour group 3). Data from the mice affected by the faulty transponders are included in food/water consumption and bodyweight analysis but not body temperature analysis ([Table 1](#tbl1){ref-type="table"}). Less than 1% of temperature readings were classed as outliers and excluded based on pre-determined criteria.

Mean change in body temperature over the course of the study predicted tumour burden in the lymph nodes (*R*^*2*^=0.68, F(1,22)=44.8, *P*\<0.001), thymus (*R*^*2*^=0.51, F(1,22)=21.6, *P*\<0.001) and spleen (*R*^*2*^=0.31, F(1,22)=9.5, *P*=0.006) at post-mortem ([Figure 2A--C](#fig2){ref-type="fig"}). Proportional change in body weight also predicted tumour burden in the lymph nodes (*R*^*2*^=0.31, F(1,22)=9.2, *P*=0.006) ([Figure 2D](#fig2){ref-type="fig"}) but not the thymus or the spleen ([Figure 2E and F](#fig2){ref-type="fig"}).

The data were examined *post-hoc* to determine whether any clinical criteria reliably predicted disease progression. At experimental and humane end points, a criterion of a mean decrease in body temperature of 0.7 °C or greater would have always detected mice with lymph nodes heavier than or equal to 0.5 g (100% sensitivity) ([Table 2](#tbl2){ref-type="table"}). Similarly a criterion of a mean decrease in body temperature \<0.7 °C would have always detected lymph nodes lighter than 0.5 grams (100% specificity) ([Table 2](#tbl2){ref-type="table"}). In contrast, although a weight loss criterion of 5% or greater would have 100% specificity for detecting lymph nodes heavier than 0.5 g, sensitivity would decrease to 60% and 40% of mice with lymph nodes heavier than 0.5 g would not have been detected ([Table 2](#tbl2){ref-type="table"}). Associations between the temperature criterion of −0.7 °C and the weight loss criterion of 5% with thymus and spleen tumour burden are summarised in [Table 2](#tbl2){ref-type="table"}.

Post-mortem findings confirmed that tumour 1 was the least aggressive primary tumour and there was an overall effect of both time (F(3,21)=3.1, *P*=0.047) and primary tumour (F(6,44)=4.3, *P*=0.002) on organ weight (lymph nodes, thymus and spleen) ([Figure 3A--C](#fig3){ref-type="fig"}). In the two cages of mice implanted with primary tumour 1, mean body weight of the animals increased over the 21 experimental days, and there was little daily variation in food or water consumption ([Figure 3D](#fig3){ref-type="fig"}). In contrast, in cages with mice implanted with primary tumours 2 and 3, mean body weight fell over the last 4--5 experimental days, and both food and water consumption began to decline from experimental day 12 ([Figure 3E and F](#fig3){ref-type="fig"}). The only clinical observation recorded over the first 12 days of the study was fighting. Clinical signs of sickness for mice implanted with tumours 2 and 3 were noted from experimental day 12 and are summarised in [Table 3](#tbl3){ref-type="table"}. Some of the clinical signs summarised in [Table 3](#tbl3){ref-type="table"} were also noted in mice implanted with tumour 1 from experimental day 17. An increase in burrowing behaviour was noted from experimental day 12 where mice were observed to move around in their homecages with their noses emerged in dirty bedding ([Figure 4](#fig4){ref-type="fig"}).

Over the first 2 weeks of the study, mean body temperature in mice implanted with all 3 primary tumours was within 0.5 °C of 36 °C ([Figure 3G--I](#fig3){ref-type="fig"}). The mean body temperature of mice implanted with primary tumours 2 and 3 decreased between experimental weeks 2 and 3 ([Figure 3H and I](#fig3){ref-type="fig"}).

Between experimental weeks 1 and 3, there was an overall decrease in both food consumption (t(4)=9.6, *P*=0.007) and water consumption (t(4)=6.9, *P*=0.0024). At the cage level, proportional decrease in food consumption (week 3 compared with week 1) predicted mean tumour burden in the lymph nodes (*R*^2^=0.89, F(1,3)=23.2, *P*=0.017) and spleen (*R*^2^=0.90, F(1,3)=27.1, *P*=0.014) but not in the thymus ([Figure 5A--C](#fig5){ref-type="fig"}). The proportional decrease in water consumption predicted tumour burden in the thymus (*R*^2^=0.83, F(1,3)=14.7, *P*=0.31) but not in the lymph nodes or spleen ([Figure 5D--F](#fig5){ref-type="fig"}).

Discussion
==========

In this study, enhanced clinical monitoring of mice implanted with E*μ*-*myc* tumours elucidated stages of disease progression. The criterion of a mean decrease in body temperature of 0.7 °C was a sensitive and specific indicator of tumour burden in lymphoid organs. As pain and distress are more likely to occur with greater tumour burdens in mice with cancer ([@bib29]), humanely killing animals when tumour burden is as required for experimental outcomes is likely to refine *in vivo* cancer studies. Humanely killing animals at a uniform stage in disease progression can also minimise variation in post-mortem findings and reduce the overall number of animals required in *in vivo* cancer research.

Our work provides further evidence to support how reliance on weight loss as a biomarker of disease progression for mice with lymphoma may be problematic ([@bib20]). Mean body weight did not begin to decrease until disease progression was relatively advanced and several animals with large tumours did not lose weight during the study.

In contrast to body weight, changes in body temperature did predict tumour burden in the lymphoid organs. One potential disadvantage of temperature as a biomarker of disease progression is the natural variability in body temperature, influenced by a large number of factors, including time of day, activity and activation of the sympathetic nervous system ([@bib24]). When studying temperature in relation to disease progression it is therefore important to be consistent in the way that temperature is taken. To minimise the effects of time of day and stress induced hyperthermia ([@bib1]), in this study mean changes in the temperature of socially housed animals in their homecage were studied and temperature was always measured in the morning typically at the transition from sleeping to waking when the lid was removed from each cage. Because of non-pathological variation in temperature and occasional outlier readings, the decision to implement a humane end point should not be made solely based on a single reading but mean changes in body temperature should be considered alongside other clinical markers (e.g., changes in appearance of the animals\' coat, demeanour, social interactions and posture). Clinical criteria that have been identified as relevant in mice with other types of lymphoma include body condition scores, general appearance (particularly coat condition) and natural behaviours (e.g., decrease in activity) ([@bib20]) as well as decreased rearing, exploration and grooming ([@bib25]). In rodents with other cancers, relevant clinical indicators include hunching and vocalisation in mice with pancreatic cancer ([@bib17]) and hunching, vocalisation and starey coats in rats with bladder cancer ([@bib22]). The further identification and dissemination of relevant clinical signs and biomarkers in mice with cancer should be encouraged ([@bib15]; [@bib29]).

The criteria of 0.7 °C decrease in body temperature and 5% weight loss were determined *post-hoc* and further studies are required to assess the predictive validity of these values. Similarly further work is needed to determine the efficacy of other non-invasive methods of measuring body temperature including thermography cameras ([@bib3]; [@bib7]) and non-contact infrared thermometers ([@bib27]) for monitoring mice with cancer.

Even if temperature is not monitored and used as a biomarker of tumour growth in mice with E*μ*-*myc* tumours, researchers should be aware that, as lymphoma develops, mice may be less able to thermoregulate. Recent studies have demonstrated that cold stress can have a negative impact on the welfare of healthy laboratory mice ([@bib8]) as well as being a source of significant experimental variability in mice with cancer ([@bib16]). Mice with E*μ*-*myc* tumours should therefore be housed with sufficient species-appropriate, naturalistic nesting material to allow the animals to carry out behavioural thermoregulation ([@bib12]; [@bib6], [@bib9]). Similarly, more consideration/investigation should be given to the most appropriate housing temperature for *in vivo* cancer studies.

At the cage level, food and water consumption was early indicator of disease onset as mean food/water consumption started to fall several days earlier than body weight or temperature. Food and water consumption has also been shown to decrease in socially housed mice with other cancers such as subcutaneous prostate cancer xenografts ([@bib13]). Measuring food/water consumption by cage requires no specialised skills or equipment and can be useful when animals are housed by the experimental group and when disease progression is similar between animals. Although it is not possible to use food/water consumption as the basis for determining individual end points in mice housed socially in individually ventilated cages, by quickly detecting the onset of clinical signs refinements such as warmth or soaked diet can be introduced to cages when most needed. When mice with lymphoma are individually housed food and water consumption also decreases with tumour growth ([@bib25]) and could therefore be used to refine individual end points.

Provided that body temperature is taken and interpreted carefully, this study indicates that it can be a useful biomarker of disease progression in mice with lymphoma and could potentially be used more widely as a biomarker for mice with other cancers.

We thank Huw Thomas, Paul Flecknell and all members of the NDP laboratory for helpful advice. CAR is funded by a National Centre for the Replacement, Refinement and Reduction of Animals in Research David Sainsbury Fellowship (grant NC/K500513/1), JEH is funded by Leukaemia and Lymphoma Research (grant 11022) and JB is funded by the Wellcome Trust (grant 094409). Additional NDP lab funding was received from Cancer Research UK programme grant C1443/A12750.

![**Position of RFID transponder reader next to homecage.** (**A**) Mice not exhibiting clinical signs of lymphoma (primary tumour 1, experimental day 20). (**B**) Mice with clinical signs of lymphoma 1 day before humane killing (primary tumour 3, experimental day 20).](bjc2013818f1){#fig1}

![**Relationships between clinical biomarkers and tumour burden.** Circles indicate 2 week endpoint, squares indicate 3 week endpoint. Tumour 1 in yellow, tumour 2 in red and tumour 3 in black. (**A--C**) Scatter plots to show relationships between change in body temperature and total weight of lymph nodes (cervical, brachial, inguinal, mesenteric), thymus and spleen. **(D--F)** Scatter plots to show relationships between change in body weight and total post-mortem weight of lymphoid organs.](bjc2013818f2){#fig2}

![**Tumour burden and changes in clinical biomarkers with disease progression.** (**A--C**) Organ weights at post-mortem classified by primary tumour implanted (mean±s.e.m.). Two week endpoints in blue, 3 week endpoints in green. (**D--F**) Changes in food/water consumption and body weight following tumour implantation on experimental day 0. Data plotted as mean±s.e.m. (mean body weight calculated from individual values; mean food/water consumption calculated from cage values). Body weight is in green, water consumption is in red and food consumption is in black. (**G--I**) Change in temperature following tumour implantation plotted as 3-day moving averages (mean+/−s.e.m.).](bjc2013818f3){#fig3}

![**Mouse exhibiting burrowing behaviour, moving forwards in the cage with his nose immersed in dirty bedding.** Picture taken on experimental day 15.](bjc2013818f4){#fig4}

![**Relationship between food/water consumption and mean tumour burden.** Tumour 1 in yellow, tumour 2 in red and tumour 3 in black. (**A--C**) Scatter plots to show relationships between decrease in food consumption and total weight of lymph nodes (cervical, brachial, inguinal, mesenteric), thymus and spleen. (**D--F**) Scatter plots to show relationships between decrease in water consumption and total post-mortem weight of lymphoid organs.](bjc2013818f5){#fig5}

###### Sample size at each endpoint

  **Time**   **Food/water consumption**   **Body weight**                                      **Body temperature**                               **Organ weight**
  ---------- ---------------------------- ---------------------------------------------------- -------------------------------------------------- -------------------------------------------------
  2 weeks    Tumours 1--3: *n*=2          Tumour 1: *n*=12 Tumour 2: *n*=11 Tumour 3: *n*=12   Tumour 1: *n*=9 Tumour 2: *n*=9 Tumour 3: *n*=11   Tumours 1--3: *n*=3
  3 weeks    Tumours 1--3: *n*=2          Tumour 1: *n*=9 Tumour 2: *n*=8 Tumour 3: *n*=9      Tumour 1: *n*=6 Tumour 2: *n*=6 Tumour 3: *n*=8    Tumour 1: *n*=3 Tumour 2: *n*=8 Tumour 3: *n*=9

###### Contingency table of clinical parameters and post-mortem organ weights

                                     **Mean change in body temperature ⩾0.7 °C**   **Change from maximum body weight ⩾5%**               
  ---------------------------------- --------------------------------------------- ----------------------------------------- ----------- ---------
  **Pooled lymph node weight (g)**                                                                                                       
  \<0.5 g                            13 (100%)                                     0 (0%)                                    13 (100%)   0 (0%)
  ⩾0.5 g                             0 (0%)                                        10 (100%)                                 4 (40%)     6 (60%)
  *P* value                                                                        \<0.0001                                              0.0021
  **Thymus weight (g)**                                                                                                                  
  \<0.2 g                            12 (92%)                                      1 (8%)                                    12 (92%)    1 (8%)
  ⩾0.2 g                             1 (10%)                                       9 (90%)                                   5 (50%)     5 (50%)
  *P-*value                                                                        0.0001                                                NS
  **Spleen weight (g)**                                                                                                                  
  \<0.3 g                            7 (88%)                                       1 (12%)                                   7 (88%)     1 (12%)
  ⩾0.3 g                             6 (40%)                                       9 (60%)                                   10 (67%)    5 (33%)
  *P*-value                                                                        NS                                                    NS

Abbreviation: NS=not significant.

###### Summary table of clinical observations noted from experimental day 12 to end points

  **Type of clinical observation**   **Terms used to describe clinical observations**
  ---------------------------------- --------------------------------------------------
  Change in coat                     Dull, starey, ruffled, decreased grooming
  Demeanour                          Dull
  Social interactions                Socially isolated, huddled
  Posture                            Hunched, ears tilted back from baseline position
  Body systems                       Pale, increased respiratory rate, sunken eyes
